A multicenter, parallel-group, double-blind, randomized, placebo-controlled, increasing-dose study, to evaluate preliminarily the clinical effects, the safety and tolerability of ABIO 08/01, in patients suffering from panic disorder.
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2012
At a glance
- Drugs BTG 1640 (Primary)
- Indications Panic disorder
- Focus Therapeutic Use
- Sponsors Abiogen Pharma
- 23 May 2008 New trial record.